What is PDUFA—and why does it matter for biotech innovators, FDA & patients?

Key takeaway: PDUFA enables the FDA to collect user fees from the biopharmaceutical industry, allowing for efficient and more predictable reviews. This funding model provides essential stability for biotech companies of all sizes and ensures the FDA maintains its status as the global leader in bringing innovative new treatments to patients.

Next year, Congress will reauthorize the Prescription Drug User Fee Act (PDUFA)—a little-known but essential law that allows the U.S. Food and Drug Administration (FDA) to collect fees from companies to support its review of new medicines. This law has provided critical stability for the agency and for the innovative companies navigating the review process. And it has enabled rigorous and efficient review of new treatments, bringing breakthroughs to patients sooner and bolstering U.S. biotech leadership.

Below is a primer on what PDUFA is, how it works, and why its user fee model is so important — for patients, biotech innovators, and the U.S. FDA.

What is PDUFA?

The Prescription Drug User Fee Act empowers the FDA to collect user fees from companies when they submit new drug applications and program fees (as outlined below).

PDUFA was enacted in 1992 to address the fact that drug reviews in the U.S. were slow, unpredictable, and under-resourced. Since then, it has transformed the U.S. drug approval process into a world-class system that brings new medicines to Americans before most other countries.

How does PDUFA work?

Under PDUFA, companies pay two types of user fees to the FDA: an application fee for each New Drug Application or Biologics License Application they submit, and a program fee for each approved application they already hold. Roughly 20% of user fee revenue comes from application fees and 80% from program fees, meaning most funding stems from successful, marketed drugs.

In return, the FDA commits to specific review timelines, meeting schedules, and process improvements. This creates a stable, predictable structure for how drugs are reviewed, which is vitally important for the biotech industry that develops the majority of new medicines. Regulatory predictability and transparency help companies secure the investment needed to fund development, plan more effectively, and avoid costly delays that can be devastating for companies with limited resources—and for the patients awaiting treatments.

Congress reauthorizes PDUFA every five years, giving the FDA an opportunity to work with biotech innovators, patients, and other stakeholders to optimize the review process and identify the necessary resources.

What do PDUFA user fees fund?

Once collected, PDUFA fees fund the FDA’s human drug review program.

User fees support a wide range of FDA activities essential to bringing innovative treatments to patients, such as reviewing investigational new drugs and applications, inspecting manufacturing facilities and product standards, and conducting studies of drugs already on the market. It is important to note that user fees are independent of review outcomes. The fee paid to submit an application has no bearing on the regulatory outcome of the review.

PDUFA does not support the review of generic or over-the-counter drugs not associated with a New Drug Application, research unrelated to human drug review, or advertising review of marketed products.

How does PDUFA benefit patients?

PDUFA has dramatically improved the speed and consistency of the drug review process, ensuring patients get access to innovative medicines sooner.

Before PDUFA became law, new drug approvals often took more than two years. Today, the FDA aims to complete standard reviews in about 10 months, and priority reviews in roughly 6 months.

The law has also made the United States a leader in approving new medicines. Before it was enacted, patients in other countries often gained access to new medicines before Americans. Today, over half of new drugs are approved first in the United States.

Finally, the law has enabled the FDA to maintain high standards while bringing safe and effective treatments to patients. Stable user fee revenue allows the agency to staff expert reviewers to keep pace with innovation, implement cutting-edge data systems, and conduct ongoing safety monitoring.

What’s the bottom line?

PDUFA is the backbone of the modern drug review system.

It helps create the conditions for new drugs to be developed by providing the stability biotech companies need to turn scientific breakthroughs into real treatments. It also ensures the FDA has the resources to keep pace with innovation and review new drugs efficiently while maintaining rigorous, independent standards.

Put simply, PDUFA provides patients with access to innovative treatments. Without it, the FDA would be less predictable, slower, and have fewer resources—resulting in fewer new therapies reaching patients.

The post What is PDUFA—and why does it matter for biotech innovators, FDA & patients? appeared first on Bio.News.